Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report-Reference-Cited by-同舟云学术

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

Published:2017-05-04 Issue:16 Volume:123 Page:3141-3149
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Schriber Jeffrey R.¹²,Hari Parameswaran N.³,Ahn Kwang Woo³⁴,Fei Mingwei³,Costa Luciano J.⁵,Kharfan‐Dabaja Mohamad A.⁶,Angel‐Diaz Miguel⁷,Gale Robert P.⁸,Ganguly Siddharatha⁹,Girnius Saulius K.¹⁰,Hashmi Shahrukh¹¹,Pawarode Attaphol¹²,Vesole David H.¹³,Wiernik Peter H.¹⁴,Wirk Baldeep M.¹⁵,Marks David I.¹⁶,Nishihori Taiga⁶,Olsson Richard F.¹⁷¹⁸,Usmani Saad Z.¹⁹,Mark Tomer M.²⁰,Nieto Yago L.²¹,D'Souza Anita³^ORCID

Affiliation:

1. Cancer Transplant InstituteVirginia G. Piper Cancer CenterScottsdale Arizona

2. Arizona OncologyScottsdale Arizona

3. Center for International Blood and Marrow Transplant ResearchDepartment of Medicine, Medical College of WisconsinMilwaukee Wisconsin

4. Department of BiostatisticsInstitute for Health and Society, Medical College of WisconsinMilwaukee Wisconsin

5. Division of Hematology/OncologyDepartment of Medicine, University of Alabama at BirminghamBirmingham Alabama

6. Department of Blood and Marrow TransplantationH. Lee Moffitt Cancer Center and Research InstituteTampa Florida

7. Department of Hematology/OncologyHospital Infantil Universitario Nino JesusMadrid Spain

8. Hematology Research CenterDivision of Experimental Medicine, Department of Medicine, Imperial College LondonLondon United Kingdom

9. Blood and Marrow TransplantationDivision of Hematology and Oncology, University of Kansas Medical CenterKansas City Kansas

10. Division of Hematology/OncologyUniversity of CincinnatiCincinnati Ohio

11. Department of Internal MedicineMayo ClinicRochester Minnesota

12. Blood and Marrow Transplantation ProgramDivision of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical SchoolAnn Arbor Michigan

13. John Theurer Cancer Center at Hackensack University Medical CenterHackensack New Jersey

14. Division of Hematology/OncologyOur Lady of Mercy Medical CenterBronx New York

15. Division of Bone Marrow TransplantSeattle Cancer Care AllianceSeattle Washington

16. Adult Bone Marrow TransplantUniversity Hospitals Bristol National Health Service TrustBristol United Kingdom

17. Division of Therapeutic ImmunologyDepartment of Laboratory Medicine, Karolinska InstituteStockholm Sweden

18. Center for Clinical Research SormlandUppsala UniversityUppsala Sweden

19. Department of Hematology and Medical OncologyLevine Cancer Institute, Carolinas HealthCare SystemCharlotte North Carolina

20. Department of MedicineWeill Cornell Medical CollegeNew York New York

21. Department of Stem Cell Transplantation and Cellular TherapyThe University of Texas MD Anderson Cancer CenterHouston Texas

Funder

Medical College of Wisconsin

National Center for Advancing Translational Sciences

National Institutes of Health

National Cancer Institute

National Heart, Lung, and Blood Institute

National Institute of Allergy and Infectious Diseases

Health Resources and Services Administration

Office of Naval Research

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30747

Reference23 articles.

1. AttalM Lauwers‐CancesV HulinC et al.Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 trial) [abstract 391]. Paper presented at: 57th Annual Meeting and Exposition of the American Society of Hematology; December 5‐8 2015; Orlando FL.

2. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

3. Upfront autologous stem cell transplantation (ASCT) versus novel agent‐based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial) [abstract];Cavo M;J Clin Oncol.,2016

4. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplant Utilization in Multiple Myeloma Have Persisted Over Time even after Referral to a Transplant Center;Transplantation and Cellular Therapy;2024-09

2. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel;Blood Cancer Journal;2024-08-27

3. Psychoneuroimmunology in multiple myeloma and autologous hematopoietic stem cell transplant: Opportunities for research among patients and caregivers;Brain, Behavior, and Immunity;2024-07

4. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities;Blood Advances;2024-06-28

5. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities;Blood Cancer Journal;2024-05-28